You can buy or sell Natera and other stocks, options, ETFs, and crypto commission-free!
Natera, Inc. engages in the discovery, development, and commercialization of genetic testing services. It offers Panorama Non-Invasive Prenatal Test, Horizon Carrier Screening, Spectrum Pre-implantation Genetic Screening and Spectrum Pre-implantation Genetic Diagnosis, Anora Products of Conception and Non-Invasive Paternity Testing. Read More The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in San Carlos, CA.
San Carlos, California
52 Week High
52 Week Low
Yahoo FinanceMay 22
Natera, Inc. Shares March Higher, Can It Continue?
As of late, it has definitely been a great time to be an investor in Natera, Inc. NTRA. The stock has moved higher by 24.3% in the past month, while it is also above its 20 Day SMA too. This combination of strong price performance and favorable technical, could suggest that the stock may be on the right path. We certainly think that this might be the case, particularly if you consider NTRA’s recent earnings estimate revision activity. From this look, the company’s future is quite favorable; as NTRA has ear...
Yahoo FinanceMay 21
Noridian Posts Favorable Draft Local Coverage Determination for Natera's Prospera™ Kidney Transplant Test
Represents Major Commercialization Milestone SAN CARLOS, Calif., May 21, 2019 /PRNewswire/ -- Noridian, the Medicare Administrative Contractor (MAC) for California-based laboratories, has posted a favorable draft local coverage determination (LCD) for use of Natera 's Prospera™ test to assess active rejection in kidney transplant recipients. Natera, Inc. Logo (PRNewsFoto/Natera, Inc.) Scroll to continue with content Ad In its LCD, Noridian states, "Prospera is an effective, non-invasive method of assess...
Yahoo FinanceMay 20
OncoCyte Catches Eye: Stock Jumps 7.3%
OncoCyte Corporation OCX was a big mover last session, as the company saw its shares rise more than 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $4.04 to $5.08 in the past one-month time frame. The company has seen one negative estimate revision in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also...
Expected Aug 7, After Hours